MedTrace Logo

Combination Chemotherapy in Treating Patients With Stage I, II, or IIIA Non-small Cell Lung Cancer That Has Been Surgically Removed

NCT00003053 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 750

Last updated 2013-09-20

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Randomized phase III trial to compare cisplatin and etoposide with no chemotherapy in treating patients who have stage I, stage II, or stage IIIA non-small cell lung cancer that has been surgically removed.

Conditions

Interventions

DRUG

cisplatin

DRUG

etoposide

PROCEDURE

adjuvant therapy

Sponsors & Collaborators

  • European Institute of Oncology

    lead OTHER

Principal Investigators

  • Antonio Nicolucci, MD · Consorzio Mario Negri Sud

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1994-01-31

Countries

  • Greece
  • Italy
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003053 on ClinicalTrials.gov